NCT06455254View on ClinicalTrials.gov

Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM

PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
CRC
Interventions
DRUG

Candonilimab (AK104)

Cadonilimab (AK104): 6mg/kg, i.v. q2w.

DRUG

Regorafenib

Regorafenib: 80 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).

Trial Locations (3)

200040

RECRUITING

Huashan Hospital, Shanghai

200072

RECRUITING

Shanghai Tenth People's Hospital, Shanghai

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Jin-hong Chen

OTHER